Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission. Printed by #UserName#, #Company_Name#


Printed By

UsernamePublicRestriction

Specials manufacturers raise concerns about cost cutting

Practice Fraud allegations could be fuelling further cuts to specials funding by CCGs, APSM survey finds

Specials manufacturers have voiced fears that fraud allegations could be fuelling further cuts to NHS spend and specials.  

The Telegraph exposé of underhand rebates had created an "unwelcome ripple through the sector" that had made many local medicines management teams wary of specials at a time when confidence and trust in the drugs had been returning, the Association of Pharmaceutical Specials Manufacturers (APSM) told C+D this month (October 7).  

The article, published in June, accused pharmacists of colluding with specials manufacturers to bill the NHS for a higher price than that paid for the drugs. This undermined some of the trust in specials created by the introduction of fixed prices for the most commonly prescribed specials in November 2011, the APSM said. 


The Telegraph exposé had created an "unwelcome ripple through the sector", the APSM said

More on specials

GPhC pledges to investigate Telegraph specials fraud exposé

Pharmacists split in response to Telegraph specials fraud exposé

Pricing authority should be vigilant for signs of specials fraud, PSNC says

Last month, the APSM published the results of its June survey, which found half of the 200 pharmacists who responded had been asked by clinical commissioning groups (CCGs) to monitor or reduce their specials dispensing. A quarter of respondents had been asked to reduce spend on specials, compared with 13 per cent in 2012.


The APSM said it was "taking a while" for prescribers to understand the impact of the specials tariff and said the fraud revelations could cause further problems.  

"Any further cost savings to be squeezed out of specials will have a minimal financial impact as the volumes are so small but could potentially have a much more significant impact on quality and patient safety," the association stressed. The NHS calculates that the specials tariff has reduced overall specials costs by 25 per cent since its introduction.  

PSNC told C+D specials were likely to be squeezed further as the NHS faced "unprecedented financial challenges" and many CCGs were exceeding their budgets.  

"PSNC has been making very clear to the NHS that CCGs must not use their new powers to manipulate delivery of community pharmacy funding, but in this sort of climate it would not be a surprise to see CCGs considering a range of options to cut costs," said Komal George, head of support services at PSNC.  

NHS England said ensuring patients received appropriate and effective treatment was the main priority for CCGs. "It is, however, absolutely right that we do this while ensuring we get the best value for the taxpayer," a spokesperson told C+D.  

Specials account for less than 1 per cent of all prescriptions, 96 per cent of spend is accounted for by the top 500 specials and, of these, more than a third are included in the tariff, the APSM said.



Have you come under pressure from your CCG to monitor or reduce your specials spending?

Comment below or email us at [email protected] You can also find C+D on Twitter, LinkedIn and Facebook

Topics



Pre-reg Trainee
Tonbridge, Kent
 Salary: £22,000
Apply Now
UsernamePublicRestriction

Register

CD016579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel